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ABSTRACT
We conducted a single-arm study to determine the biodistribution of intraperitoneally (i.p.) administered
90yttrium-labeled murine monoclonal antibody HMFG1 (90Y-muHMFG1) in patients with advanced stage
ovarian cancer. Seventeen (17) patients in complete clinical remission for epithelial ovarian cancer were
included. After completion of chemotherapy, a mixture of 111indium-labeled muHMFG1 (imaging) and
90Y-muHMFG1 (therapy) was i.p. administered by a surgically placed, indwelling i.p. catheter. Planar
and single-photon emission computed tomography images were recorded to determine the distribution of
the study medication during the first 6 days postinjection. Of the first 3 patients, 2 patients had ex-
traperitoneal leakage of up to 50% of the injected dose within 24 hours after injection of the study med-
ication. Extraperitoneal leakage was mainly seen in the retroperitoneal spaces covering the upper and
lower quadrant of the abdomen. After adjustments in the procedure, leakage was observed in 2 of the re-
maining 14 patients. Extraperitoneal leakage of i.p. administered therapy does occur. Such leakage would
reduce the locally delivered dose of a drug and could potentially have a negative impact on therapeutic
efficacy. Given the potential attraction of developing i.p. treatments for intra-abdominal cancer, the ob-
servations in this study need to be taken into consideration.
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INTRODUCTION
Despite advances in the treatment of ovarian can-
cer, it is still the most deadly of the gynecologic
malignancies. In the majority of cases, it is diag-
nosed at an advanced stage, when 5-year survival
is 25%–30%.1 Although there is a high response
rate to cytoreductive surgery followed by plat-
inum-based chemotherapy, the majority of pa-
tients develop recurrent disease, particularly in
the abdominal cavity. Failure to control intra-ab-
dominal disease remains the primary reason for
poor overall outcome.
Intraperitoneal (i.p.) delivery of antineoplastic
therapy was first explored in the 1950s, and over
the last five decades several forms of intraperi-
toneal therapy (e.g., i.p. chemotherapy, i.p. ra-
dioimmunotherapy, i.p. radioactive P-32 phos-
phate, and i.p. unlabeled monoclonal antibody
[mAb] therapy) have been investigated in patients
with ovarian, colorectal, and gastric cancer.2 Ad-
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vantages of i.p. therapy are the achievement of
higher local drug concentrations, which can
greatly exceed drug concentrations in the plasma,
reduced systemic toxicity, prolonged tumor ex-
posure with an assumed greater effect on tumor
reduction, and a slow systemic uptake from the
peritoneal cavity.3,4 The different i.p. therapy
forms have shown variable results.
Despite advantages of an i.p. approach, i.p.
studies have not yet led to a standardization of
i.p. therapy in ovarian cancer. At least three ran-
domized studies have shown a survival benefit
for the use of i.p. chemotherapy in ovarian can-
cer patients, with residual disease smaller than 2
cm in diameter after debulking surgery.5–7 How-
ever, toxicity and difficulties inherent to this ap-
proach have, until recently, precluded its accep-
tance into clinical practice.4,8,9
In a phase III, randomized, clinical trial, a
novel approach using an i.p. injection of the
HMFG1 murine mAb radiolabeled with 90-
yttrium was studied.10 HMFG1 is directed toward
the MUC1 gene, which is a large, heavily glyco-
sylated mucin expressed on the apical surface of
the majority of secretory epithelial cells.11 In
90% of the epithelial ovarian cancers, MUC1 is
overexpressed on the cell surface and it is anti-
genically distinct from normal tissue mucin as a
result of underglycosylation or aberrant glycosy-
lation of this protein in cancerous tissue.12,13
Parallel to the phase III study,10 we conducted
an open, single-arm study to determine the
biodistribution of the i.p. administered therapeu-
tic agent 90yttrium-labeled murine HMFG1 (90Y-
muHMFG1).
PATIENTS AND METHODS
Between July 2001 and July 2004, patients in
complete clinical remission following cytoreduc-
tive surgery and platinum-based chemotherapy
for a prior histologic proven diagnosis of epithe-
lial ovarian cancer FIGO stages Ic–IV were en-
rolled in the Monoclonal Antibody Imaging and
Dosimetry Assessment Study (MIDAS). The
study was approved by the Institutional Review
Board of the Radboud University Nijmegen Med-
ical Centre (Nijmegen, The Netherlands). Writ-
ten, informed consent was obtained from all pa-
tients prior to study entry. Eligibility criteria
consisted of proven epithelial ovarian cancer, in-
cluding primary peritoneal serous carcinoma with
ovarian involvement, entry within 4–8 weeks
from final administration of chemotherapy, a life
expectancy of at least 3 months, an age over 18
years, and adequate bone marrow (leukocyte
count  3  109/L, platelet count  100 
109/L, hemoglobin 10 g/dL), renal (serum crea-
tinine  177 mol/L or 20 mg/L), and hepatic
function (alanine aminotransferase and aspartate
aminotransferase not higher than twice the upper
limit of normal). Patients were excluded from in-
clusion in the study if they had known metastases
at the time of second-look laparoscopy (SLL) or
had prior or concomitant malignancy other than
basal cell carcinoma of the skin. Further exclu-
sion criteria were: serious concomitant physical
or psychiatric disease, previous exposure to
murine antibodies or the presence of human-an-
timouse antibodies (HAMA) as detected by the
central laboratory, and participation in any other
experimental treatment program.
During SLL, the trocar for the laparoscope was
placed inferior and the trocar for the laparoscopic
probe inferior and lateral to the umbilicus. If there
was any visible evidence of malignant disease at
SLL, the patient was excluded from the study. At
negative SLL, the patient was further enrolled in
the study and the peritoneal dialysis catheter was
placed at the same place as the trocar for the lap-
aroscopic probe and was fixated to the abdomi-
nal wall. Administration of the study medication
was performed 1 day after SLL through the peri-
toneal dialysis catheter. Before administering ra-
diolabeled antibody, 99mtechnetium (99mTc) col-
loid was injected i.p. to verify an adequate fluid
distribution within the peritoneal cavity. Signif-
icant loculation of the i.p. cavity—that might
preclude adequate distribution of the study med-
ication—was excluded by the initial i.p. admin-
istration of 99mTc-colloid. After the adminis-
tration of 99mTc-colloid-colloid, the patient was
moved frequently to ensure adequate intra-ab-
dominal distribution. Subsequently, anterior and
posterior planar images were recorded to check
the adequate distribution of the radiopharma-
ceutical to all four abdominal quadrants. When
distribution was seen in at least 3 of the 4 ab-
dominal quadrants, 0.5 L of saline solution,
heated to body temperature, was infused. There-
after, a single therapeutic dose of 90Y-muHMFG1
(Antisoma, London, UK; 90Y activity dose 666
MBq/m2 of body-surface area with a maximum
dose, but not exceeding 1110 MBq) spiked with
an imaging dose of 185 MBq of 111indium-
muHMFG1was injected through the “Y” con-
nector or two-way tap in 30–60 seconds. Al-
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though obviously not necessary for imaging and
dosimetry studies, it was decided to offer the ther-
apeutic 90Y-muHMFG1 to patients participating
in this study, as patients were subjected to all the
same invasive procedures as the patients in the
active treatment arm of the phase III trial that was
recruiting in parallel. During and after the infu-
sion of the radiopharmaceuticals, the saline solu-
tion continued to flow until the i.p. space was
filled with 1.5 L of saline solution. After the ad-
ministration of the study medication, the cathe-
ter was removed and the skin was closed. To en-
hance the distribution of the study medication in
the peritoneal cavity, the patient was asked to
move gently during the first hour after adminis-
tration.
Planar and single-photon emission computed
tomography (SPECT) images were recorded to
determine the distribution of the study medica-
tion. On the anterior and posterior images, re-
gions of interest (ROIs) were drawn around the
extraperitoneal leakage (corrected for back-
ground by an ROI drawn in the adjacent soft tis-
sues in which no leakage was observed) and over
the whole body. When drawing the ROIs over the
extraperitonel leakage, the inclusion of intra-ab-
dominal activity was carefully avoided. At all
time points, the measured counts in ROIs were
corrected for the physical decay of 111indium.
SPECT was performed twice at 48 and 168 hours
postinjection for dosimetric calculations (data not
shown), but not used for the assessment of leak-
age. The percentage of leakage was calculated by
using the geometric means of the decay-corrected
counts in the following formula:
 ((ROIleakage, ant  ROIbkgr, ant)
 (ROIleakage, post  ROIbkgr, post))
(ROIWB, ant, t0  ROIWB, post,t0)
Blood sampling and imaging was performed at
1, 6, 24, 48, 72, 96, 120, and 168 hours after in-
jection of the study medication, with a range of
4 hours. Blood samples were collected,
weighed, and counted in a -counter. By simul-
taneous measurement of a known aliquot of the
injected dose, the percentage injected dose per
gram (%ID/g) was determined for each sample.
For safety purposes, patients had a weekly fol-
low-up for 6 weeks, then at weeks 8 and 12, and
3 months thereafter, up to 1 year posttreatment.
The follow-up consisted of a physical examina-
tion, as well as blood and urine sampling to de-
termine total activity that was excreted.
Statistical Analyses
Data analyses were performed by using the SPSS
12.0.1 software packet (SPSS Inc.; Chicago, IL).
Differences between characteristics were tested
as two-sided with the independent t test. P-val-
ues 0.05 were considered significant.
RESULTS
A total of 17 patients received the i.p. study med-
ication of the MIDAS study (Table 1). In the first
3 patients, 2 cases of substantial leakage from the
peritoneal cavity to extraperitoneal spaces were
observed. Patient 1 showed a moderate ex-
traperitoneal leakage of approximately 11% of
the injected study medication into the right-lower
quadrant of the abdomen. Patient 3 had a major
extraperitoneal leakage of 50% of the injected ac-
tivity into the right-upper and -lower quadrant of
the abdomen (Fig. 1). These observations resulted
in an adjustment of the protocol. After the first 3
patients, the protocol was revised and adjusted
with the following measures: first, the trocar in-
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Table 1. Baseline Characteristics of 17 Patients Treated with Intraperitoneal 90Y-muHMFG1
FIGO stage No. of patients Serous Papillary Endometroid Other
IIb 1 1 — — —
IIIa 2 2 — — —
IIIb 6 3 — 1 2a
IIIc 7 4 2 1 —
IV 1 1 — — —
FIGO, International Federation of Gynecology and Obstetrics.
aOne unspecified and one mixed endometroid and serous carcinoma.
cision for the laparoscopic probe and catheter was
displaced from the lateral to the medial side of
the abdomen. Second, the peritoneal dialysis
catheter was replaced by a Foley catheter (Eu-
romedical; Lynge, Denmark) to ensure that the
abdominal opening would be closed firmly; the
balloon of the Foley catheter was inflated, pulled
back, and secured against the abdominal wall
with sutures before the administration of the
study medication. Third, the infusion of distribu-
tion fluid was limited to a maximum volume of
1 L. Finally, instead of removing the catheter im-
mediately after administration of the study med-
ication, the catheter remained in situ for a mini-
mum of 24 hours after the administration of the
study medication.
After the introduction of these four adjustment
measures, no leakage was observed in 12 of the
14 remaining patients. Patient 13 showed a very
minor leakage of 2.5% of the injected dose into
the left-lower quadrant of the abdomen, and in
patient 17, a moderate extraperitoneal leakage of
19% into the right flank and lower quadrant of
the abdomen was seen.
The minimum time at which extraperitoneal
leakage first was seen was as early as 4 hours af-
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Figure 1. (A) Whole-body images of patient 3 at 24 hours postinjection of 111indium-muHMFG1: Major extraperitoneal leak-
age (50% of the injected activity leaked into the right-upper and -lower quadrant of the abdomen), and (B) whole-body images
of patient 9 at 24 hours postinjection of 111indium-muHMFG1 without extraperitoneal leakage.
A B
ter the injection of the study medication, as de-
fined on planar images. All 4 patients with ex-
traperitoneal leakage had signs of leakage at 24
hours after the injection of the study medication.
In none of these 4 patients were local side-effects
caused by increased radiation outside the peri-
toneal cavity observed.
Radioactivity in blood serum was measured at
time points 1, 6, 24, 48, 72, 96, and 168 hours
postinjection of the study medication. As shown
in Figure 2, the 3 patients with substantial leak-
age (patients 1, 3, and 17) had a 50% lower peak
activity in their blood at 48 hours after an i.p. in-
jection. Furthermore, subsequent blood clearance
of the radioactivity from 48 to 168 hours after the
study drug administration was slower than in the
group without leakage, indicating a slow release
and reabsorption from the extraperitoneal com-
partment to the blood. There was a significant dif-
ference in the level of blood radioactivity (area un-
der the curve) between the group of patients
without leakage (1.12  0.45) and the 3 patients
with substantial leakage (0.50  0.12; p  0.001).
DISCUSSION
Four (4) of the 17 patients demonstrated leakage
after an i.p. administration of study medication.
After adjusting the surgical procedure and the in-
fusion method, leakage was reduced, but not
completely prevented. Leakage of the study med-
ication did not result in local toxicity resulting
from radiation exposure.
To date, no studies or case reports about the
leakage of i.p.-administered medication to ex-
traperitoneal spaces, which was not subcutaneous
(s.c.), have been described in the literature.
Balink et al.14 reported a case of leakage into the
s.c. tissue at the catheter site after i.p. therapy
with 32P during the treatment of malignant as-
cites. They detected the leakage because of re-
gional side-effects after the administration of the
study medication. As found in our study, the leak-
age of i.p. study medication does not always
cause side-effects. This depends on the amount
of leakage, the site of leakage, and the composi-
tion of the study medication. Different chemot-
herapeutic agents that have been used i.p. are
classified as vesicant and irritant drugs, which
may cause inflammation and/or tissue destruc-
tion.15
Major catheter problems, such as malfunction,
did not occur in our study, but these have been
reported in other studies. Several studies reported
that 10%–50% of the patients treated with i.p.
chemotherapy had catheter problems. Reported
complications were malfunction of the catheter
(inflow obstruction), infection, bowel perfora-
tion, ileus, abdominal pain, and an increased mor-
bidity.16–19 Almost all these complications were
reported in studies that used repeated adminis-
trations of the drugs. Because 90Y-muHMFG1
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Figure 2. Radioactivity in the blood after an intraperitoneal administration of 111indium-muHMFG1. There is a significant dif-
ference between the blood levels of 111 In-muHMFG1 in patients with leakage (Leakage 	) and patients without leakage (Leak-
age ). Data are expressed as means of the two groups.
tration procedure, which was less invasive. Place-
ment of the catheter during surgery and quick re-
moval of the catheter after drug administration
prevented extra surgical interventions and cathe-
ter complication. For repeated administration, the
technique we have described in this paper is not
appropriate, as it was designed for a one-time ad-
ministration of i.p. therapy.
Recommendations for the use and placement
of i.p. catheters for repeated drug administrations
have been given by Markman and Walker20 and
were the following: (i) the insertion of a fully im-
plantable port attached to a single lumen venous
silicone catheter on the inferior thorax at the mid-
clavicular line; (ii) the catheter should be tun-
neled s.c., above the fascia, 6 cm lateral to the
umbilicus, and pulled into the peritoneal cavity
through a small hole the size of the catheter; and
(iii) closure of the wound and peritoneal defect
in several layers to prevent leakage.20
In our study, we restricted the use of distribu-
tion fluid in the i.p. cavity to 1 L at maximum af-
ter the first 3 patients. Several i.p. chemotherapy
studies have used 1.5–2 liters of distribution fluid
at maximum to facilitate the distribution of med-
ication.5–7,21–25 The rationale behind minimizing
the volume of distribution fluid was for a poten-
tially lower i.p. pressure and, hence, to minimize
the risk of leakage. Dedrick and Flessner26 dem-
onstrated that an increase in irrigated area may
be achieved in many patients by individualizing
the distribution fluid volume and through the con-
sideration of the patient’s position. Obviously—
as in our study, both the surgical protocol and the
distribution volume were modified—it is unclear
which alteration had more impact on the reduc-
tion of leakage.
The main problem with regional therapy is the
limited depth of penetration of the drugs directly
into the tumor by free-surface diffusion. Experi-
mental and clinical data support the conclusions
that the high concentrations of drugs observed af-
ter delivery directly into the peritoneal cavity will
only be relevant for patients with microscopic
disease or very small-volume macroscopic can-
cer (e.g., largest residual mass less than 0.5–1.0
cm in diameter).27,28 In this context, the existence
of leakage during i.p. therapy is of importance
for the outcome of the treatment. Leakage may
result in lower concentrations in the i.p. cavity
and thereby potentially diminish the effects of the
drug. If the surfaces of tumor nodules are not, or
are inadequately exposed to the drug-containing
solution, the rationale for regional administration
is compromized and treatment failures could re-
sult. A recently published large international ran-
domized trial of i.p. 90Y-muHMFG1 in ovarian
cancer patients did not show a survival benefit
between the active treatment and the standard
treatment arm.10 This might, at least in part, be
owing to leakage after i.p. therapy, possibly re-
sulting in diminished therapeutic effectiveness.
Besides working as a regional therapy, i.p.
therapy could also be effective in the systemic
treatment of any extraperitoneal tumor localiza-
tions. Capillary uptake of the drug from the peri-
toneal cavity allows for the therapeutic concen-
trations to be achieved systematically, resulting
in the control of extraperitoneal disease. As
shown in Figure 2, the group with leakage shows
a lower concentration in the blood, as compared
to the group without leakage. The concentration
in the peritoneal cavity is lower, which causes a
lower gradient for the diffusion of the radioac-
tivity and clearance out of the peritoneal cavity.
Thus, when leakage occurs, it may affect not only
the i.p. therapy, but also possible systemic ef-
fects.
Some phase III trials have documented the clin-
ical benefit of i.p. cisplatin-based chemotherapy
in the first-line treatment of optimally cytore-
duced patients.5–7 The results of i.p. chemother-
apeutic therapy when extraperitoneal leakage oc-
curs are not yet known. The effect on efficacy
and the local side-effects largely depends on the
reabsorption from the extraperitoneal tissues.
CONCLUSIONS
In conclusion, significant extraperitoneal leak-
age of i.p.-administered medication may occur,
which may result in decreased efficacy and po-
tentially also in local side-effects. In view of
the recently published clinical announcement of
the National Cancer Institute to prefer a com-
bination of i.p. and i.v. chemotherapy over i.v.
chemotherapy alone in the first-line treatment
of ovarian cancer29 and future developments of
i.p. treatment of intra-abdominal cancer, the ob-
servations in this study need to be taken into
consideration.
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